Precision BioSciences Inc (DTIL)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Precision BioSciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 7.00 $ — 60% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 322.9% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.71 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.69 | – | 1 | -90.90 | -2,781.30 | -19 | -19 |
| 2025: Q1 | -0.80 | -339.50 | 0 | -99.80 | -70,913.80 | -19 | -19 |
| 2025: Q2 | -0.91 | -171.80 | 0 | -100.00 | -130,666.70 | -20 | -20 |
| 2025: Q3 | -0.84 | – | 0 | -97.70 | -167,476.90 | -15 | -15 |
| 2025: Q4 | 0.75 | – | 34 | 5,261.10 | 56.30 | -11 | -11 |
| 2026: Q1 | -0.71 | – | 11 | 37,272.40 | -170.20 | -12 | -12 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Precision BioSciences, Inc., ein Gen-Editing-Unternehmen in der klinischen Phase, entwickelt In-vivo-Gen-Editing-Therapien für Geneditierungen wie Gen-Insertion, -Exzision und -Eliminierung in den USA.
| Employees | 66 |
|---|---|
| Headquarters | Durham, NC |
| Website | precisionbiosciences.com |
| IPO Date | 28. Mar 2019 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Michael Amoroso | President, CEO & Director | 1978 |
| John Alexander Kelly R.Ph. | CFO & Principal Accounting Officer | 1967 |
| Dario Scimeca J.D. | General Counsel & Secretary | 1975 |
| Jefferson J. Smith Ph.D. | Co-Founder & Chief Research Officer | 1973 |
| Cassie Gorsuch Ph.D. | Chief Scientific Officer | – |
| Naresh Tanna | Chief of Staff to CEO & Head of Investor Relations | – |
| Juli Blanche | Chief People Officer | – |
| Cindy Atwell | Chief Development & Business Officer | – |
| Neil Leatherbury M.S. | Senior VP and Head of Chemistry, Manufacturing & Controls | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.